DD223359A5 - Verfahren zur herstellung eines perkutanen pharmazeutischen praeparates - Google Patents

Verfahren zur herstellung eines perkutanen pharmazeutischen praeparates Download PDF

Info

Publication number: DD223359A5
Authority: DD; German Democratic Republic
Prior art keywords: molsidomine; atoms; preparation; acid; aliphatic
Prior art date: 1983-05-26

Application number

DD84263301A

Other languages

German (de)

English (en)

Inventor

Masayuki Yamada

Yoshiaki Uda

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-05-26

Filing date

1984-05-23

Publication date

1985-06-12

1983-05-26 Priority claimed from JP9315383A external-priority patent/JPS59216818A/ja

1984-03-23 Priority claimed from JP5692384A external-priority patent/JPS60199834A/ja

1984-05-23 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

1985-06-12 Publication of DD223359A5 publication Critical patent/DD223359A5/de

Links

238000004519 manufacturing process Methods 0.000 title description 5
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 40
229940124532 absorption promoter Drugs 0.000 claims abstract description 22
-1 aliphatic monocarboxylic acid Chemical class 0.000 claims abstract description 21
238000002360 preparation method Methods 0.000 claims abstract description 18
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 12
125000001931 aliphatic group Chemical group 0.000 claims abstract description 11
238000000034 method Methods 0.000 claims abstract description 9
229960004027 molsidomine Drugs 0.000 abstract description 40
XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 abstract description 40
238000010521 absorption reaction Methods 0.000 abstract description 36
239000008280 blood Substances 0.000 abstract description 14
210000004369 blood Anatomy 0.000 abstract description 14
125000004429 atom Chemical group 0.000 abstract 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
239000000203 mixture Substances 0.000 description 19
239000003814 drug Substances 0.000 description 17
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 14
229940079593 drug Drugs 0.000 description 14
210000003491 skin Anatomy 0.000 description 10
239000000243 solution Substances 0.000 description 10
241000700159 Rattus Species 0.000 description 8
239000011248 coating agent Substances 0.000 description 8
238000000576 coating method Methods 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000005639 Lauric acid Substances 0.000 description 7
238000011156 evaluation Methods 0.000 description 7
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 7
230000000144 pharmacologic effect Effects 0.000 description 7
229920006395 saturated elastomer Polymers 0.000 description 7
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 6
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 6
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 6
239000005642 Oleic acid Substances 0.000 description 6
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 6
239000004743 Polypropylene Substances 0.000 description 6
229960002896 clonidine Drugs 0.000 description 6
230000007774 longterm Effects 0.000 description 6
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
229920001155 polypropylene Polymers 0.000 description 6
239000004166 Lanolin Substances 0.000 description 5
239000002253 acid Substances 0.000 description 5
150000001298 alcohols Chemical class 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
235000019388 lanolin Nutrition 0.000 description 5
229940039717 lanolin Drugs 0.000 description 5
230000036470 plasma concentration Effects 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
230000037374 absorbed through the skin Effects 0.000 description 4
239000000853 adhesive Substances 0.000 description 4
230000001070 adhesive effect Effects 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 4
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 4
239000004745 nonwoven fabric Substances 0.000 description 4
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
229940068918 polyethylene glycol 400 Drugs 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
239000004698 Polyethylene Substances 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
238000011835 investigation Methods 0.000 description 3
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
229940093430 polyethylene glycol 1500 Drugs 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 2
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 2
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
235000021357 Behenic acid Nutrition 0.000 description 2
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000002390 adhesive tape Substances 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Polymers [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
239000010775 animal oil Substances 0.000 description 2
229940114079 arachidonic acid Drugs 0.000 description 2
235000021342 arachidonic acid Nutrition 0.000 description 2
229940116226 behenic acid Drugs 0.000 description 2
210000000038 chest Anatomy 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 2
238000001035 drying Methods 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000011888 foil Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
210000004209 hair Anatomy 0.000 description 2
KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
XMHIUKTWLZUKEX-UHFFFAOYSA-N hexacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O XMHIUKTWLZUKEX-UHFFFAOYSA-N 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
239000000463 material Substances 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
239000011259 mixed solution Substances 0.000 description 2
FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
UTOPWMOLSKOLTQ-UHFFFAOYSA-N octacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O UTOPWMOLSKOLTQ-UHFFFAOYSA-N 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
229960002446 octanoic acid Drugs 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000007789 sealing Methods 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
VHOCUJPBKOZGJD-UHFFFAOYSA-N triacontanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O VHOCUJPBKOZGJD-UHFFFAOYSA-N 0.000 description 2
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
229940099259 vaseline Drugs 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000019300 CLIPPERS Diseases 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
239000004821 Contact adhesive Substances 0.000 description 1
206010052895 Coronary artery insufficiency Diseases 0.000 description 1
229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
239000004348 Glyceryl diacetate Substances 0.000 description 1
244000043261 Hevea brasiliensis Species 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
235000021353 Lignoceric acid Nutrition 0.000 description 1
CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
239000005643 Pelargonic acid Substances 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002367 Polyisobutene Polymers 0.000 description 1
239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
VBVMEMKHGAKMEC-UHFFFAOYSA-N [C].C(CCCCCCCCCCC)N Chemical compound [C].C(CCCCCCCCCCC)N VBVMEMKHGAKMEC-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000007824 aliphatic compounds Chemical class 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Polymers [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
229920003064 carboxyethyl cellulose Polymers 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229940107161 cholesterol Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
239000007931 coated granule Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
239000004205 dimethyl polysiloxane Substances 0.000 description 1
229960000520 diphenhydramine Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229960000735 docosanol Drugs 0.000 description 1
ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000003925 fat Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
235000019443 glyceryl diacetate Nutrition 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
210000003780 hair follicle Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
229920006262 high density polyethylene film Polymers 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
WVWDMDSWVYUDRU-UHFFFAOYSA-N n-decylhexadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCNCCCCCCCCCC WVWDMDSWVYUDRU-UHFFFAOYSA-N 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
LYRFLYHAGKPMFH-UHFFFAOYSA-N octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
QWIDXEUVWSDDQX-SVMKZPJVSA-N octadecanoic acid;(z)-octadec-9-enoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O QWIDXEUVWSDDQX-SVMKZPJVSA-N 0.000 description 1
KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
235000014593 oils and fats Nutrition 0.000 description 1
FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000000123 paper Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000011049 pearl Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000012466 permeate Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920002239 polyacrylonitrile Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
229940057847 polyethylene glycol 600 Drugs 0.000 description 1
229940085675 polyethylene glycol 800 Drugs 0.000 description 1
229920000139 polyethylene terephthalate Polymers 0.000 description 1
239000005020 polyethylene terephthalate Substances 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
229920002050 silicone resin Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012177 spermaceti Substances 0.000 description 1
229940084106 spermaceti Drugs 0.000 description 1
229940032094 squalane Drugs 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
229920003051 synthetic elastomer Polymers 0.000 description 1
239000005061 synthetic rubber Substances 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
229940005605 valeric acid Drugs 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DD84263301A 1983-05-26 1984-05-23 Verfahren zur herstellung eines perkutanen pharmazeutischen praeparates DD223359A5 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP9315383A JPS59216818A (ja)	1983-05-26	1983-05-26	経皮吸収外用製剤
JP5692384A JPS60199834A (ja)	1984-03-23	1984-03-23	経皮吸収外用製剤

Publications (1)

Publication Number	Publication Date
DD223359A5 true DD223359A5 (de)	1985-06-12

Family

ID=26397929

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD84263301A DD223359A5 (de)	1983-05-26	1984-05-23	Verfahren zur herstellung eines perkutanen pharmazeutischen praeparates

Country Status (9)

Country	Link
US (1)	US4731241A (da)
EP (1)	EP0127468B1 (da)
CA (1)	CA1216239A (da)
DD (1)	DD223359A5 (da)
DE (1)	DE3480262D1 (da)
DK (1)	DK243084A (da)
ES (1)	ES532812A0 (da)
HU (1)	HU191659B (da)
NO (1)	NO842103L (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4931283A (en) *	1983-12-22	1990-06-05	American Home Products Corp. (Del)	Menthol enhancement of transdermal drug delivery
US4933184A (en) *	1983-12-22	1990-06-12	American Home Products Corp. (Del)	Menthol enhancement of transdermal drug delivery
DE3346638A1 (de) *	1983-12-23	1985-07-04	Cassella Ag, 6000 Frankfurt	Photostabilisierung von molsidomin
IL72684A (en) *	1984-08-14	1989-02-28	Israel State	Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4818540A (en) *	1985-02-25	1989-04-04	Rutgers, The State University Of New Jersey	Transdermal fertility control system and process
DE3685895T2 (de) *	1985-02-25	1992-12-24	Univ Rutgers	Dosierungssystem fuer transdermale absorption von arzneimittelwirkstoffen.
CA1288698C (en) *	1985-08-30	1991-09-10	Rutgers, The State University Of New Jersey	Transdermal anti-anginal pharmaceutical dosage
US4764381A (en) *	1985-12-06	1988-08-16	Key Pharmaceuticals, Inc.	Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US5560922A (en) *	1986-05-30	1996-10-01	Rutgers, The State University Of New Jersey	Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
MY102980A (en) *	1986-10-31	1993-03-31	Pfizer	Transdermal flux enhancing compositions
US5196410A (en) *	1986-10-31	1993-03-23	Pfizer Inc.	Transdermal flux enhancing compositions
US4971800A (en) *	1988-07-08	1990-11-20	The Regents Of The University Of California	Method and compositions for enhancing the cutaneous penetration of pharmacologically active agents
US5051260A (en) *	1987-07-16	1991-09-24	The Regents Of The University Of California	Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
US5045317A (en) *	1987-07-16	1991-09-03	The Regents Of The University Of California	Enhancing the cutaneous penetration of pharmacologically active agents
DE3729299A1 (de) *	1987-09-02	1989-03-23	Beiersdorf Ag	Transdermales therapeutisches system
CN1035925C (zh) *	1988-11-16	1997-09-24	许正	亲细胞非均质分子脂质的制备方法
EP0399432B1 (en) *	1989-05-25	1994-06-22	Takeda Chemical Industries, Ltd.	Transdermal therapeutic composition
HU210921B (en) *	1990-03-28	1995-09-28	Chinoin Gyogyszer Es Vegyeszet	Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
US5149719A (en) *	1990-04-27	1992-09-22	Minnesota Mining And Manufacturing Company	Composition for transdermal penetration of medicaments
US5296514A (en) *	1991-04-23	1994-03-22	Summit Technology, Inc.	Corneal treatment agents
US5098896A (en) *	1991-04-23	1992-03-24	Summit Technology, Inc.	Corneal treatment agents
US5214071A (en) *	1991-04-23	1993-05-25	Summit Technology, Inc.	Corneal treatment agents
US5358715A (en) *	1992-09-02	1994-10-25	Cygnus Therapeutic Systems	Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
DE4305881C1 (de) *	1993-02-26	1994-03-03	Lohmann Therapie Syst Lts	Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung
US5804214A (en) *	1993-07-08	1998-09-08	Cygnus, Inc.	Monolithic matrix transdermal delivery system for delivering ketorolac tromethamine
AU7977294A (en) *	1993-10-07	1995-05-01	Odontex, Inc.	Absorption enhancers for topical pharmaceutical formulations
DE59509232D1 (de) *	1994-02-18	2001-06-13	Drossapharm Ag Basel	Transdermales therapeutisches System
US5484608A (en) *	1994-03-28	1996-01-16	Pharmavene, Inc.	Sustained-release drug delivery system
WO1996011022A1 (en) *	1994-10-05	1996-04-18	Hisamitsu Pharmaceutical Co., Inc.	DRUG COMPOUNDING INGREDIENTS COMPRISING N-SUBSTITUTED-o-TOLUIDINE DERIVATIVE AND PERCUTANEOUSLY ABSORBABLE PREPARATION
US5985316A (en) *	1995-04-28	1999-11-16	Alza Corporation	Composition and method of enhancing electrotransport agent delivery
US5990179A (en) *	1995-04-28	1999-11-23	Alza Corporation	Composition and method of enhancing electrotransport agent delivery
US5707612A (en) *	1996-04-08	1998-01-13	Alzo, Inc.	Use urethane polymers of castor oil skin and personal care product compositiions
US6414028B1 (en)	1997-11-05	2002-07-02	Nexmed Holdings, Inc.	Topical compositions containing prostaglandin E1
US6046244A (en) *	1997-11-05	2000-04-04	Nexmed Holdings, Inc.	Topical compositions for prostaglandin E1 delivery
CN109640976B (zh) *	2016-08-22	2023-10-17	救急药品工业株式会社	贴附剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LU34976A1 (da) *
DE2924005C2 (de) *	1979-06-13	1984-07-05	Sanol Schwarz-Monheim Gmbh, 4019 Monheim	Isosorbiddinitrat enthaltendes Mittel
JPS56133381A (en) *	1980-03-25	1981-10-19	Nippon Kayaku Co Ltd	Pressure-sensitive adhesive tape or sheet containing nitroglycerin
JPS57116011A (en) *	1981-01-08	1982-07-19	Nitto Electric Ind Co Ltd	Pharmaceutical preparation
DE3107933A1 (de) *	1981-03-02	1982-09-16	Cassella Ag, 6000 Frankfurt	Substituierte 3-amino-sydnonimine, verfahren zu ihrer herstellung und ihre verwendung
GB2105990B (en) *	1981-08-27	1985-06-19	Nitto Electric Ind Co	Adhesive skin patches

1984
- 1984-05-17 DK DK243084A patent/DK243084A/da not_active Application Discontinuation
- 1984-05-23 DD DD84263301A patent/DD223359A5/de unknown
- 1984-05-25 HU HU842049A patent/HU191659B/hu unknown
- 1984-05-25 CA CA000455119A patent/CA1216239A/en not_active Expired
- 1984-05-25 DE DE8484303559T patent/DE3480262D1/de not_active Expired
- 1984-05-25 EP EP84303559A patent/EP0127468B1/en not_active Expired
- 1984-05-25 NO NO842103A patent/NO842103L/no unknown
- 1984-05-25 ES ES532812A patent/ES532812A0/es active Granted
1987
- 1987-03-09 US US07/022,515 patent/US4731241A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DK243084A (da)	1984-11-27
CA1216239A (en)	1987-01-06
HUT35515A (en)	1985-07-29
ES8602774A1 (es)	1985-12-01
EP0127468B1 (en)	1989-10-25
EP0127468A2 (en)	1984-12-05
EP0127468A3 (en)	1986-03-19
ES532812A0 (es)	1985-12-01
DE3480262D1 (en)	1989-11-30
HU191659B (en)	1987-03-30
US4731241A (en)	1988-03-15
DK243084D0 (da)	1984-05-17
NO842103L (no)	1984-11-27

Publication	Publication Date	Title
DE69822199T2 (de)	2005-02-17	Arzneimittel und verfahren zur behandlung von aufmerksamkeitsstörungen und aufmerksamkeits-/hyperaktivitätsstörungen mit methylphenidat
DE69401945T3 (de)	2004-09-02	Einarbeitung eines poly-n-vinylamids in ein transdermales system
DE3751383T2 (de)	1996-01-11	Feste Vorrichtungen zur transdermalen Wirkstoffabgabe, die Fettsäureester bzw. Fettalkoholether von Alkandiole als Absorptionsförderer verwenden.
DE60021099T2 (de)	2006-05-18	Transdermale, in form einer haftschicht ausgebildete zweifachmedikamenten-verabreichungsvorrichtung
EP0377147B1 (de)	1994-05-11	Transdermales therapeutisches System mit Physostigmin als wirksamem Bestandteil und Verfahren zu seiner Herstellung
DE69326461T2 (de)	2000-05-04	Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung
DE69430917T2 (de)	2003-03-20	3-l-MENTHOXY-PROPANE-1, 2-DIOL ALS LÖSUNGSVERMITTLER UND EXTERNE ZUBEREITUNG, DIE DIESEN ENTHÄLT
DE68907406T2 (de)	1993-10-14	Deprenyl zur systemischen transdermalen anwendung.
DE3587698T2 (de)	1994-04-28	Pharmazeutische Präparate.
DE60311449T2 (de)	2007-11-08	Transdermales therapeutisches system mit zwei übereinanderliegenden matrixschichten, die verschiedene affinitäten zum enthaltenen wirkstoff ausweisen
CH646876A5 (de)	1984-12-28	Arzneimittel enthaltendes hautpflaster und verfahren zu dessen herstellung.
WO1994016707A1 (de)	1994-08-04	Transdermales therapeutisches system mit galanthamin als wirksamen bestandteil
EP0127468A2 (en)	1984-12-05	Percutaneous pharmaceutical preparations for external use
DE69735656T2 (de)	2006-08-24	Vorrichtung zur transdermalen Verabreichung von Fluoxetin
EP0538433A1 (de)	1993-04-28	Mittel zur transdermalen applikation enthaltend ergolin-derivate
CH643456A5 (de)	1984-06-15	Pharmazeutische zubereitung.
EP0584126B1 (de)	1997-04-16	Lanolinderivate als penetrationsfördernde substanzen
DE69322328T2 (de)	1999-06-24	Transdermal Alfuzosin enthaltendes Arztneimittel
WO1996008251A1 (de)	1996-03-21	Scopolaminpflaster
WO2000048579A1 (de)	2000-08-24	Desoxypeganin-tts
DE68911444T2 (de)	1994-05-11	Selbstklebende Vorrichtung zur transdermalen Verabreichung eines Wirkstoffs.
DE69628672T2 (de)	2004-04-29	Transdermale verabreichung von risperidon mit kontrollierter geschwindigkeit
DE68928533T2 (de)	1998-07-02	Untergesättigte transdermale abgabevorrichtung
DE3782594T2 (de)	1993-06-03	Arzneimittel zur transdermalen verabreichung von nicorandil.
EP2366388A1 (de)	2011-09-21	Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin